What resistance rate is typical for acyclovir (HSV or VZV)?
Yes, but only in broad ranges, because reported rates depend heavily on which virus (HSV vs VZV), which patient group (immunocompetent vs transplant/HIV), how resistance is defined (phenotypic vs genotypic), and which drugs were used before testing. Across clinical practice and literature, acyclovir resistance in herpes viruses is generally uncommon in people with normal immune function, and much more common in patients with prolonged or repeated antiviral exposure, especially those with advanced immunosuppression.
How do rates differ between HSV and VZV?
Reports usually show:
- HSV: resistance is low in immunocompetent patients, but rises substantially in people with chronic infection or heavy antiviral exposure (for example, transplant recipients or advanced HIV).
- VZV: resistance patterns are less frequently discussed than HSV, and reported rates also vary by immunosuppression level and treatment history.
Without the specific setting and virus type, any “estimate” will be too uncertain to be clinically useful.
Why are resistance rates hard to estimate from routine data?
A few reasons:
- Not everyone with treatment failure gets resistance testing; testing tends to occur after prolonged disease, so the measured “rate” may reflect a selected, higher-risk group.
- Genotypic testing (e.g., detecting polymerase or kinase-related mutations) and phenotypic testing (showing reduced susceptibility) don’t always map 1:1 to the same “resistance rate.”
- “Acyclovir resistance” can be reported as resistance to acyclovir specifically, or broader nucleoside analog resistance (which may include valacyclovir/famciclovir).
What patient factors most change the estimated probability?
Resistance probability is higher when there is:
- Advanced or prolonged immunosuppression
- Long courses or repeated exposure to acyclovir/valacyclovir
- Chronic lesions or persistent viral shedding despite therapy
These are the populations where clinicians most often see resistance and where published estimates (when they exist) are highest.
If you’re estimating for a study or clinic, what inputs do you need?
To produce an estimate that’s even directionally plausible, you’d typically need:
- Virus: HSV-1, HSV-2, or VZV
- Immune status: immunocompetent vs transplant vs HIV (and CD4 level if HIV)
- Treatment history: number/duration of prior nucleoside analog courses
- Outcome definition: virologic failure vs clinical nonresponse
- Testing method: phenotypic vs genotypic, and which mutations/thresholds count as resistance
If you share those details, I can translate them into a tighter, more defensible range and explain how the estimate would change under different assumptions.
Quick check: which scenario do you mean?
1) Resistance in genital/oral HSV in otherwise healthy people
2) Resistance in transplant or advanced HIV
3) Resistance in VZV (e.g., zoster)
4) Resistance after treatment failure in a specific cohort
Reply with the virus type and patient context (and whether this is for HSV or VZV), and I’ll give the best possible resistance-rate estimate for that scenario.